Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00711269
Recruitment Status : Completed
First Posted : July 8, 2008
Last Update Posted : June 13, 2012
Information provided by:
Sumitomo Dainippon Pharma Co., Ltd.

Brief Summary:
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: SM-13496 (lurasidone HCl) Drug: Placebo Drug: Risperidone Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 440 participants
Primary Purpose: Treatment
Official Title: Randomized, Placebo-controlled, Double-blind, Parallel-group, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase III Study>
Study Start Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: 1 Drug: SM-13496 (lurasidone HCl)
Lurasidone HCl: 40 mg/day

Experimental: 2 Drug: SM-13496 (lurasidone HCl)
Lurasidone HCl: 80 mg/day

Placebo Comparator: 3 Drug: Placebo
Active Comparator: 4 Drug: Risperidone

Primary Outcome Measures :
  1. Change from baseline in PANSS total score

Secondary Outcome Measures :
  1. Efficacy: Change from baseline in the PANSS total score by subscales etc. Safety: Proportion of subjects with Adverse Events (AEs), Discontinuations due to AEs, and Serious Adverse Events (SAEs).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Patient meets DSM-IV criteria for schizophrenia.
  • Patient is 18 or older but younger than 75 years of age on the day of signing informed consent.
  • Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent.

Main Exclusion Criteria:

  • Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
  • Patient has Parkinson's disease.
  • Patient has a history or complication of malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00711269

Japan: 45 sites
Tokyo, etc., Japan
Korea, Republic of
Korea: 10 sites
Seoul, etc., Korea, Republic of
Taiwan: 7 sites
Taipei, etc., Taiwan
Sponsors and Collaborators
Sumitomo Dainippon Pharma Co., Ltd.
Study Director: Drug Development Division Dainippon Sumitomo Pharma Co., Ltd. Identifier: NCT00711269     History of Changes
Other Study ID Numbers: D1001002
First Posted: July 8, 2008    Key Record Dates
Last Update Posted: June 13, 2012
Last Verified: June 2012

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Lurasidone Hydrochloride
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Adrenergic alpha-2 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Serotonin 5-HT2 Receptor Antagonists
Dopamine D2 Receptor Antagonists